• Something wrong with this record ?

SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients

A. Agaimy, MB. Amin, AJ. Gill, B. Popp, A. Reis, DM. Berney, C. Magi-Galluzzi, M. Sibony, SC. Smith, S. Suster, K. Trpkov, O. Hes, A. Hartmann,

. 2018 ; 77 (-) : 139-146. [pub] 20180422

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19028467

Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive RCC type, originally described in the setting of hereditary leiomyomatosis and RCC syndrome, which is defined by germline FH gene inactivation. Inactivation of components of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex is involved in renal medullary carcinoma (SMARCB1/INI1 loss), clear cell RCC (PBRM1 loss), and subsets of dedifferentiated RCC of clear cell, chromophobe, and papillary types (loss of different SWI/SNF components). FH-RCC and SWI/SNF-deficient RCC share anaplastic nuclear features and highly aggressive course. We analyzed 32 FH-RCCs from 28 patients using 7 commercially available SWI/SNF antibodies (SMARCB1/INI1, SMARCA2, SMARCA4, SMARCC1, SMARCC2, PBRM1, and ARID1A). Variable loss of SMARCB1, ARID1A, and SMARCC1 was observed in 1 of 31, 2 of 31, and 1 of 29 evaluable cases, respectively; 3 of these 4 SWI/SNF-deficient tumors had confirmed FH mutations. No correlation of SWI/SNF loss with solid or sarcomatoid features was observed. Two tumors with SMARCB1 and ARID1A deficiency had available SWI/SNF molecular data; both lacked SMARCB1 and ARID1A mutations. The remaining 5 SWI/SNF components were intact in all cases. Especially PBRM1 seems not to be involved in the pathogenesis or progression of FH-RCC. Our data showed that a subset of FH-RCC (12%) have a variable loss of SWI/SNF complex subunits, likely as secondary genetic events. This should not be confused with SWI/SNF-deficient RCC of other types. Evaluation of FH and SWI/SNF together with comprehensive molecular genetic profiling is needed to explore possible prognostic implications of FH/SWI-SNF double deficiency and to better understand the somatic mutation landscape in high-grade RCC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028467
003      
CZ-PrNML
005      
20190822124435.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.humpath.2018.04.004 $2 doi
035    __
$a (PubMed)29689242
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Agaimy, Abbas $u Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital of Erlangen, 91054 Erlangen, Germany. Electronic address: abbas.agaimy@uk-erlangen.de.
245    10
$a SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients / $c A. Agaimy, MB. Amin, AJ. Gill, B. Popp, A. Reis, DM. Berney, C. Magi-Galluzzi, M. Sibony, SC. Smith, S. Suster, K. Trpkov, O. Hes, A. Hartmann,
520    9_
$a Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive RCC type, originally described in the setting of hereditary leiomyomatosis and RCC syndrome, which is defined by germline FH gene inactivation. Inactivation of components of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex is involved in renal medullary carcinoma (SMARCB1/INI1 loss), clear cell RCC (PBRM1 loss), and subsets of dedifferentiated RCC of clear cell, chromophobe, and papillary types (loss of different SWI/SNF components). FH-RCC and SWI/SNF-deficient RCC share anaplastic nuclear features and highly aggressive course. We analyzed 32 FH-RCCs from 28 patients using 7 commercially available SWI/SNF antibodies (SMARCB1/INI1, SMARCA2, SMARCA4, SMARCC1, SMARCC2, PBRM1, and ARID1A). Variable loss of SMARCB1, ARID1A, and SMARCC1 was observed in 1 of 31, 2 of 31, and 1 of 29 evaluable cases, respectively; 3 of these 4 SWI/SNF-deficient tumors had confirmed FH mutations. No correlation of SWI/SNF loss with solid or sarcomatoid features was observed. Two tumors with SMARCB1 and ARID1A deficiency had available SWI/SNF molecular data; both lacked SMARCB1 and ARID1A mutations. The remaining 5 SWI/SNF components were intact in all cases. Especially PBRM1 seems not to be involved in the pathogenesis or progression of FH-RCC. Our data showed that a subset of FH-RCC (12%) have a variable loss of SWI/SNF complex subunits, likely as secondary genetic events. This should not be confused with SWI/SNF-deficient RCC of other types. Evaluation of FH and SWI/SNF together with comprehensive molecular genetic profiling is needed to explore possible prognostic implications of FH/SWI-SNF double deficiency and to better understand the somatic mutation landscape in high-grade RCC.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a karcinom z renálních buněk $x genetika $x patologie $7 D002292
650    _2
$a chromozomální proteiny, nehistonové $x metabolismus $7 D002868
650    _2
$a DNA-helikasy $x genetika $x metabolismus $7 D004265
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fumarasa $x nedostatek $7 D005649
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a nádory ledvin $x genetika $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a jaderné proteiny $x genetika $x metabolismus $7 D009687
650    _2
$a transkripční faktory $x genetika $x metabolismus $7 D014157
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Amin, Mahul B $u Department of Pathology and Laboratory Medicine, University of Tennessee Health Sciences, Memphis, TN 38103, USA.
700    1_
$a Gill, Anthony J $u University of Sydney NSW Australia 2006, Cancer Diagnosis and Pathology Group, Kolling Institute, Royal North Shore Hospital NSW Australia 2065 and NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
700    1_
$a Popp, Bernt $u Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
700    1_
$a Reis, André $u Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
700    1_
$a Berney, Daniel M $u Barts Cancer Institute, Queen Mary University of London, London ECIM 6BQ, UK.
700    1_
$a Magi-Galluzzi, Cristina $u Cleveland Clinic, Cleveland, OH 44195, USA.
700    1_
$a Sibony, Mathilde $u Hospital Cochin, 75679 Paris, France.
700    1_
$a Smith, Steven C $u Department of Pathology, VCU School of Medicine, Richmond, VA 23298, USA.
700    1_
$a Suster, Saul $u Medical College of Wisconsin, Milwaukee, WI 53226, USA.
700    1_
$a Trpkov, Kiril $u Calgary Laboratory Services and University of Calgary, Calgary, Alberta, Canada.
700    1_
$a Hes, Ondřej $u Charles University and University Hospital Plzen, 304 60 Plzen, Czech Republic.
700    1_
$a Hartmann, Arndt $u Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital of Erlangen, 91054 Erlangen, Germany.
773    0_
$w MED00002080 $t Human pathology $x 1532-8392 $g Roč. 77, č. - (2018), s. 139-146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29689242 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822124713 $b ABA008
999    __
$a ok $b bmc $g 1433616 $s 1066927
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 77 $c - $d 139-146 $e 20180422 $i 1532-8392 $m Human pathology $n Hum Pathol $x MED00002080
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options